Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting

Vakaramoko Diaby, Ching Yu Wang, Hussain Alqhtani, Sascha van Boemmel-Wegmann, Askal Ayalew Ali, Rajesh Balkrishnan, Yu Ko, Sofia Palacio, Gilberto de Lima Lopes

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


The present data article aims to describe the input parameters for a Markov model assessing the cost-effectiveness of four treatment sequences for patients with HER-2 positive metastatic breast cancer. The model input parameters include costs for physician visits, drugs, adverse event management, computed tomography (CT) scan, laboratory tests, echocardiogram, utilities, disutilities as well as the shape and scale parameters of a log-logistic distribution used for the transition probabilities.

Original languageEnglish
Article number105194
JournalData in Brief
Publication statusPublished - Apr 2020


  • Cost-effectiveness analysis
  • Markov model
  • Metastatic breast cancer
  • Treatment sequence

ASJC Scopus subject areas

  • General

Cite this